# TNFAIP2

## Overview
TNFAIP2, or tumor necrosis factor alpha-induced protein 2, is a gene that encodes a protein involved in various cellular processes, particularly in the context of immune response and cancer biology. The protein encoded by TNFAIP2 is categorized as an adaptor protein, which plays a crucial role in mediating interactions between different signaling molecules. It is known to participate in pathways that regulate inflammation, apoptosis, and cellular stress responses. TNFAIP2 has been implicated in the modulation of drug resistance mechanisms, particularly in cancer types such as triple-negative breast cancer and head and neck squamous cell carcinoma, where it interacts with key signaling pathways to influence cell survival and proliferation (Fang2023Integrin; Xu2023TNFAIP2). Additionally, genetic variations in TNFAIP2 have been associated with disease susceptibility and prognosis, highlighting its clinical significance in conditions like septic shock and various cancers (Lin2022Pancancer; Thair2015TNFAIP2).

## Clinical Significance
The TNFAIP2 gene is implicated in various diseases and conditions, particularly in the context of cancer and inflammatory responses. In septic shock, genetic variations in TNFAIP2, specifically the SNP rs8126, are associated with patient outcomes. The G allele of rs8126 is linked to increased TNFAIP2 protein levels, leading to greater inhibition of NF-κB signaling, which may result in immunosuppression and higher mortality rates in septic shock patients (Thair2015TNFAIP2).

In cancer, TNFAIP2 is associated with increased risk and poor prognosis in several types. The rs8126 polymorphism is linked to a higher risk of esophageal squamous cell carcinoma (ESCC), with the CC genotype associated with lower TNFAIP2 mRNA levels in normal tissues (Zhang2014A). In acute myeloid leukemia (AML), TNFAIP2 overexpression correlates with poor survival outcomes and unfavorable cytogenetic risk (Lin2022Pancancer). TNFAIP2 also contributes to cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) by interacting with the KEAP1/NRF2 signaling pathway, which affects oxidative stress response and drug resistance (Xu2023TNFAIP2).

## Interactions
TNFAIP2 interacts with several proteins, playing a significant role in various cellular processes. In triple-negative breast cancer (TNBC), TNFAIP2 interacts with IQGAP1 and Integrin β4 (ITGB4), forming a complex that activates the RAC1 protein. This interaction is crucial for promoting drug resistance and enhancing DNA damage repair in TNBC cells. The TNFAIP2/IQGAP1/RAC1 axis is identified as a potential therapeutic target to overcome drug resistance in TNBC (Fang2023Integrin).

TNFAIP2 also interacts with the KEAP1/NRF2 signaling pathway in head and neck squamous cell carcinoma (HNSCC). It stabilizes the NRF2 protein by inhibiting its ubiquitination and degradation, which enhances NRF2 signaling and contributes to cisplatin resistance. TNFAIP2 binds to the Kelch domain of KEAP1 via its DLG motif, preventing NRF2 from undergoing ubiquitin proteasome-mediated degradation. This interaction leads to the accumulation of NRF2, promoting the transcription of antioxidant genes and reducing apoptosis (Xu2023TNFAIP2).

In acute myeloid leukemia (AML), TNFAIP2 is involved in immunological modulation and interacts with numerous genes, influencing pathways such as myeloid leukocyte activation and cytokine signaling (Lin2022Pancancer).


## References


[1. (Fang2023Integrin) Huan Fang, Wenlong Ren, Qiuxia Cui, Huichun Liang, Chuanyu Yang, Wenjing Liu, Xinye Wang, Xue Liu, Yujie Shi, Jing Feng, and Ceshi Chen. Integrin β4 promotes dna damage-related drug resistance in triple-negative breast cancer via tnfaip2/iqgap1/rac1. eLife, October 2023. URL: http://dx.doi.org/10.7554/elife.88483, doi:10.7554/elife.88483. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.88483)

[2. (Thair2015TNFAIP2) Simone A. Thair, Elena Topchiy, John H. Boyd, Mihai Cirstea, Catherine Wang, Taka-aki Nakada, Christopher D. Fjell, Mark Wurfel, James A. Russell, and Keith R. Walley. Tnfaip2 inhibits early tnfa-induced nf-&amp;#954;b signaling and decreases survival in septic shock patients. Journal of Innate Immunity, 8(1):57–66, September 2015. URL: http://dx.doi.org/10.1159/000437330, doi:10.1159/000437330. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000437330)

[3. (Zhang2014A) Jian Zhang, Hongchen Yu, Yi Zhang, Xiaoshi Zhang, Guixin Zheng, Yang Gao, Chuanxin Wang, and Liqing Zhou. A functional tnfaip2 3’-utr rs8126 genetic polymorphism contributes to risk of esophageal squamous cell carcinoma. PLoS ONE, 9(11):e109318, November 2014. URL: http://dx.doi.org/10.1371/journal.pone.0109318, doi:10.1371/journal.pone.0109318. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0109318)

[4. (Xu2023TNFAIP2) Teng Xu, Yuemei Yang, Zhihong Chen, Jinsong Wang, Xiaolei Wang, Yang Zheng, Chao Wang, Yachen Wang, Zaiou Zhu, Xu Ding, Junbo Zhou, Gang Li, Hongchuang Zhang, Wei Zhang, Yunong Wu, and Xiaomeng Song. Tnfaip2 confers cisplatin resistance in head and neck squamous cell carcinoma via keap1/nrf2 signaling. Journal of Experimental &amp; Clinical Cancer Research, August 2023. URL: http://dx.doi.org/10.1186/s13046-023-02775-1, doi:10.1186/s13046-023-02775-1. This article has 11 citations.](https://doi.org/10.1186/s13046-023-02775-1)

[5. (Lin2022Pancancer) Mei-si Lin, Hui-Yun Zhong, Rita Lok-Hay Yim, Qi-Yan Chen, Hong-ling Du, Hao-qi He, Ke Lin, Peng Zhao, Ru Gao, Fei Gao, and Min-Yue Zhang. Pan-cancer analysis of oncogenic tnfaip2 identifying its prognostic value and immunological function in acute myeloid leukemia. BMC Cancer, October 2022. URL: http://dx.doi.org/10.1186/s12885-022-10155-9, doi:10.1186/s12885-022-10155-9. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-022-10155-9)